Awakn Life Sciences (AWKN.NE) announced it has received ethical approval to conduct the first-ever study of the effects of ketamine on gambling addiction. Awakn has begun to recruit patients…
Psychedelics
Mindset Pharma (MSET.C) announced they have filed a new patent with the US Patent and Trade Office (USPTO), extending its Family 4 compounds, a set of novel DMT/5-MeO-DMT analogs….
Mind Medicine (MNMD.Q, MMED.NE) announced that they have agreed to partner with Forian (FORA.Q), who provide evidence-based support for clinical and commercial decision making. Forian and MindMed will collaborate…
Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public…
Novamind (NM.CN) is a company that addresses mental health. Utilizing a network of psychiatry clinics, research sites and therapeutic retreats specialized in psychedelic medicine. The company states they are…
This week, news from the psychedelic sector has been dominated by patent applications and earnings being released. Here’s the run down of this week’s news. Cybin (CYBN.NE) It’s been…
Mydecine Innovations Group (MYCO.NE) announced they have signed a five-year research agreement with Johns Hopkins University (JHU) School of Medicine. The research will be led by Dr. Matthew Johnson…
Revive Therapeutics (RVV.C) announced they are entering into an exclusive license agreement with Puerto Rico Science Technology and Research Trust (PRSTRT) for the intellectual property titled ‘Biologically Active Ganoderma…
NeonMind Biosciences (NEON.C) announced that they have received approval from Health Canada on the product license application for their ‘Mindful Blend’ functional mushroom product. The Mindful Blend functional mushroom…
Cybin (CYBN.NE) announced they are filing a new non-provisional patent application, their 14th patent application. The decision comes after what they called “a favourable international search report” relating to…